These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23218601)

  • 1. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
    Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
    Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.
    Oumata N; Bettayeb K; Ferandin Y; Demange L; Lopez-Giral A; Goddard ML; Myrianthopoulos V; Mikros E; Flajolet M; Greengard P; Meijer L; Galons H
    J Med Chem; 2008 Sep; 51(17):5229-42. PubMed ID: 18698753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
    Dong K; Wang X; Yang X; Zhu X
    J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
    Vandromme L; Piguel S; Lozach O; Meijer L; Legraverend M; Grierson DS
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3144-6. PubMed ID: 16616489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.
    Nair N; Kudo W; Smith MA; Abrol R; Goddard WA; Reddy VP
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3957-61. PubMed ID: 21641213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
    Otyepka M; Bártová I; Kríz Z; Koca J
    J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of CDK5/p25 binding by CDK inhibitors.
    Mapelli M; Massimiliano L; Crovace C; Seeliger MA; Tsai LH; Meijer L; Musacchio A
    J Med Chem; 2005 Feb; 48(3):671-9. PubMed ID: 15689152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors.
    Vandromme L; Legraverend M; Kreimerman S; Lozach O; Meijer L; Grierson DS
    Bioorg Med Chem; 2007 Jan; 15(1):130-41. PubMed ID: 17064911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors.
    Rzasa RM; Kaller MR; Liu G; Magal E; Nguyen TT; Osslund TD; Powers D; Santora VJ; Viswanadhan VN; Wang HL; Xiong X; Zhong W; Norman MH
    Bioorg Med Chem; 2007 Oct; 15(20):6574-95. PubMed ID: 17697781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
    Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
    Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
    Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors.
    Kaller MR; Zhong W; Henley C; Magal E; Nguyen T; Powers D; Rzasa RM; Wang W; Xiong X; Norman MH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6591-4. PubMed ID: 19864130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and kinase inhibitory activity of novel substituted indigoids.
    Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
    Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors.
    Bruel A; Logé C; Tauzia ML; Ravache M; Le Guevel R; Guillouzo C; Lohier JF; Oliveira Santos JS; Lozach O; Meijer L; Ruchaud S; Bénédetti H; Robert JM
    Eur J Med Chem; 2012 Nov; 57():225-33. PubMed ID: 23063566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.
    Wilkaniec A; Gąssowska-Dobrowolska M; Strawski M; Adamczyk A; Czapski GA
    J Neuroinflammation; 2018 Jan; 15(1):1. PubMed ID: 29301548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.
    Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS
    Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.
    Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
    Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.